Home | Welcome to Contract Pharma   
Last Updated Thursday, September 18 2014
Print

Amgen To Build Bio-Facility In Singapore



Published January 17, 2013
Related Searches: Manufacturing
Amgen plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore, investing approximately $200 million. The facility will initially focus on expanding manufacturing capabilities for monoclonal antibodies, and will be capable of manufacturing both clinical and commercial products. Construction is expected to begin in the next few months, and the site will be staffed with both new recruits and experienced staff.

"Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment," said Madhu Balachandran, executive vice president of Operations at Amgen.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On